Leptomeningeal carcinomatosis in gastric cancer: a case report of a rare yet aggressive entity
Abstract
##plugins.themes.bootstrap3.article.details##
leptomeningeal carcinomatosis, gastric cancer, advanced cancer, intrathecal chemotherapy
2. Pentheroudakis G, Pavlidis N. Management of leptomeningeal malignancy. Expert Opin Pharmacother. 2005; 6:1115-1125.
3. Kim M. Intracranial involvement by metastatic advanced gastric carcinoma. J Neurooncol. 1999; 43(1):59-62.
4. Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017; 28(Suppl. 4):iv84–iv99.
5. Kwon J, Chie EK, Kim K, et al. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014; 29(8):1094–1101.
6. Kountourakis P, Papamichael D, Haralambous H, et al. Leptomeningeal metastases originated from esophagogastric junction/gastric cancer: A brief report of two cases. World J Gastrointest Oncol. 2018; 10(1):56-61.
7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11-20.
8. Giglio P, Weinberg JS, Forman AD, Wolff R, D Groves M. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 2005; 103:2355-2362.
9. Liu Y. Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review. Cancer Biol Ther. 2017; 18(10):761-764.
10. Park KK, Yang SI, Seo KW, Kim YO, Yoon KY. A case of metastatic leptomeningeal carcinomatosis from early gastric carcinoma. World J Surg Oncol. 2012; 10:74.
11. Chowdhary S, Chamberlain M. Leptomeningeal metastases: Current Concepts and Management Guidelines. JNCCN. 2005; 3(5).
12. Chamberlain MC. Leptomeningeal metastasis. Current Opin Oncol. 2010; 22(6):627-635.
13. Groves MD. New strategies in the management of leptomeningeal metastases. Arch Neurol. 2010; 67(3):305-312.
14. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010; 11:871-879.
15. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006; 78:255-260. Erratum in: J Neurooncol. 2006; 78(3):261. Shah, Gaurav G [corrected to Shah, Gaurav D].
16. Kak M, Nanda R, Ramsdale EE, Lukas RV. Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci. 2015; 22(4):632-637.
17. Fakih M, Schiff D, Erlich R. Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases. Ann Oncol. 2001; 12(8):1173–1177.
18. Lee SH, Kong DS, Seol HJ, Nam DH, Lee JI. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol. 2011; 104:545-551.
19. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008; 19:1978-1980.
20. Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32:2039-2049.
21. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-697. Erratum in: Lancet. 2010; 376(9749):1302.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.